Actually I was referring to HALO specifically. The JUNO deal, of course, caused a stir in biotech in general but I was wondering if their technology, which appears to mesh well with what HALO has to offer, might therefore provoke some deal-making with HALO as a third dance partner. The stock movement seems to indicate that as a possibility. I agree, though, that the ph 3 results might have to precede such things, but maybe not?
Good luck!
-Fritz
News 
Market Data 
Discover 
